Diagnostic utility of galectin-3 in thyroid cancer

American Journal of Pathology

Volumn 176, Issue 5, 2010, Pages 2067-2081

  Chiu, Connie G ^a   Strugnell, Scott S ^a   Griffith, Obi L ^a   Jones, Steven J M ^a   Gown, Allen M ^a,b   Walker, Blair ^a   Nabi, Ivan R ^a   Wiseman, Sam M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PHENOPATH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; GALECTIN 3;

ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER GROWTH; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CYTOLOGY; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCORING SYSTEM; THYROID CARCINOMA; THYROID GLAND; THYROIDITIS; TISSUE SECTION;

EID: 77952019606     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090353     Document Type: Review

References (135)

1. Gharib H, Papini E: Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am 2007, 36:707-735, vi
2. Gharib H: Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin Proc 1994, 69:44-49
3. Wiseman SM, Baliski C, Irvine R, Anderson D, Wilkins G, Filipenko D, Zhang H, Bugis S: Hemithyroidectomy: the optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm. Ann Surg Oncol 2006, 13:425-432 (Pubitemid 43255927)
4. Melck A, Bugis S, Baliski C, Irvine R, Anderson DW, Wilkins G, Zhang H, Wiseman SM: Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. Am J Surg 2006, 191:593-597 (Pubitemid 44389523)
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:109-142
6. Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, Jones SJ, Griffith OL: Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol 2008, 15:2811-2826
7. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffler H, Liu F-T, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PWJ, Rini JM, Wang: Galectins: a family of animal beta-galactoside- binding lectins. Cell 1994, 76:597-598
8. Hsu DK, Zuberi RI, Liu FT: Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin. J Biol Chem 1992, 267:14167-14174
9. Mehul B, Bawumia S, Hughes RC: Cross-linking of galectin 3, a galactose-binding protein of mammalian cells, by tissue-type transglutaminase. FEBS Lett 1995, 360:160-164
10. Ahmad N, Gabius HJ, Andre S, Kaltner H, Sabesan S, Roy R, Liu B, Macaluso F, Brewer CF: Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 2004, 279:10841-10847
11. Liu FT, Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 2005, 5:29-41
12. Dumic J, Dabelic S, Flogel M: Galectin-3: an open-ended story. Biochim Biophys Acta 2006, 1760:616-635
13. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D: The MUC1 and galectin-3 oncoproteins function in a microRNA- dependent regulatory loop. Mol Cell 2007, 27:992-1004 (Pubitemid 47488189)
14. Nieminen J, Kuno A, Hirabayashi J, Sato S: Visualization of galectin- 3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem 2007, 282:1374-1383 (Pubitemid 47076550)
15. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, Nabi IR, Wrana JL, Dennis JW: Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 2004, 306:120-124 (Pubitemid 39451953)
16. Lajoie P, Partridge EA, Guay G, Goetz JG, Pawling J, Lagana A, Joshi B, Dennis JW, Nabi IR: Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol 2007, 179:341-356 (Pubitemid 350004897)
17. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, Raz A: The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 1999, 59:6239-6245 (Pubitemid 30035648)
18. Xu XC, el-Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995, 147:815-822
19. Yang RY, Hsu DK, Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996, 93:6737-6742 (Pubitemid 26230379)
20. Paron I, Scaloni A, Pines A, Bachi A, Liu FT, Puppin C, Pandolfi M, Ledda L, Di Loreto C, Damante G, Tell G: Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 2003, 302:545-553
21. Lin CI, Whang EE, Abramson MA, Donner DB, Bertagnolli MM, Moore FD Jr, Ruan DT: Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 2009, 379:626-631
22. Shi Y, He B, Kuchenbecker KM, You L, Xu Z, Mikami I, Yagui-Beltran A, Clement G, Lin YC, Okamoto J, Bravo DT, Jablons DM: Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer 2007, 121:1175-1181
23. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A: Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997, 57:5272-5276 (Pubitemid 27516362)
24. Yu F, Finley RL Jr, Raz A, Kim HR: Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002, 277:15819-15827 (Pubitemid 34967860)
25. Cecchinelli B, Lavra L, Rinaldo C, Iacovelli S, Gurtner A, Gasbarri A, Ulivieri A, Del Prete F, Trovato M, Piaggio G, Bartolazzi A, Soddu S, Sciacchitano S: Repression of the antiapoptotic molecule galectin- 3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 2006, 26:4746-4757
26. Lavra L, Ulivieri A, Rinaldo C, Dominici R, Volante M, Luciani E, Bartolazzi A, Frasca F, Soddu S, Sciacchitano S: Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol 2009, 218:66-75
27. Fukumori T, Takenaka Y, Oka N, Yoshii T, Hogan V, Inohara H, Kanayama HO, Kim HR, Raz A: Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 2004, 64:3376-3379 (Pubitemid 38657907)
28. Liu L, Sakai T, Sano N, Fukui K: Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J 2004, 380:31-41 (Pubitemid 38725726)
29. Takenaka Y, Inohara H, Yoshii T, Oshima K, Nakahara S, Akahani S, Honjo Y, Yamamoto Y, Raz A, Kubo T: Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 2003, 195:111-119
30. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, Raz A: Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 1998, 115:287-296 (Pubitemid 28363421)
31. van den Brule F, Califice S, Castronovo V: Expression of galectins in cancer: a critical review, Glycoconj J 2004, 19:537-542
32. Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL: Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002, 12:329-337
33. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A: Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277:6852-6857 (Pubitemid 34953068)
34. Takenaka Y, Fukumori T, Raz A: Galectin-3 and metastasis. Glycoconj J 2004, 19:543-549
35. Califice S, Castronovo V, Bracke M, van den Brule F: Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004, 23:7527-7536 (Pubitemid 39389694)
36. Dennis JW, Laferte S: Oncodevelopmental expression of-GlcNAc beta 1-6Man alpha 1-6Man beta 1-branched asparagine-linked oligosaccharides in murine tissues and human breast carcinomas. Cancer Res 1989, 49:945-950
37. Miyoshi E, Nishikawa A, Ihara Y, Saito H, Uozumi N, Hayashi N, Fusamoto H, Kamada T, Taniguchi N: Transforming growth factor beta up-regulates expression of the N-acetylglucosaminyltransferase V gene in mouse melanoma cells. J Biol Chem 1995, 270:6216-6220
38. Yao M, Zhou DP, Jiang SM, Wang QH, Zhou XD, Tang ZY, Gu JX: Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma. J Cancer Res Clin Oncol 1998, 124:27-30 (Pubitemid 28129111)
39. Murata K, Miyoshi E, Kameyama M, Ishikawa O, Kabuto T, Sasaki Y, Hiratsuka M, Ohigashi H, Ishiguro S, Ito S, Honda H, Takemura F, Taniguchi N, Imaoka S: Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res 2000, 6:1772-1777
40. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW: Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 1991, 51:718-723
41. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW: Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med 2000, 6:306-312 (Pubitemid 30148623)
42. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW: Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 2007, 129:123-134 (Pubitemid 46507588)
43. Lagana A, Goetz JG, Cheung P, Raz A, Dennis JW, Nabi IR: Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol 2006, 26:3181-3193
44. Goetz JG, Joshi B, Lajoie P, Strugnell SS, Scudamore T, Kojic LD, Nabi IR: Concerted regulation of focal adhesion dynamics by galectin- 3 and tyrosine-phosphorylated caveolin-1. J Cell Biol 2008, 180:1261-1275 (Pubitemid 351468479)
45. Dennis JW, Lau KS, Demetriou M, Nabi IR: Adaptive regulation at the cell surface by N-glycosylation. Traffic 2009, 10:1569-1578
46. Lajoie P, Goetz JG, Dennis JW, Nabi IR: Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol 2009, 185:381-385
47. Griffith OL, Chiu CG, Gown AM, Jones SJ, Wiseman SM: Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev Anticancer Ther 2008, 8:1399-1413
48. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A: Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998, 58:3015-3020 (Pubitemid 28335081)
49. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A: Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 1999, 17:3494-3502 (Pubitemid 29517920)
50. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T: Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999, 85:2475-2484
51. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001, 357:1644-1650
52. Saggiorato E, Cappia S, De Giuli P, Mussa A, Pancani G, Caraci P, Angeli A, Orlandi F: Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001, 86:5152-5158
53. Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A, Kuribayashi T, Hirai K, Nabeshima K, Kotani T: Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol 2002, 26:366-372
54. Papotti M, Volante M, Saggiorato E, Deandreis D, Veltri A, Orlandi F: Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma. Eur J Endocrinol 2002, 147:515-521
55. Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S: Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn Cytopathol 2004, 31:392-396
56. Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B, Cappia S, Conticello S, Papotti M, Orlandi F: Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest 2004, 27:311-317
57. Collet JF, Hurbain I, Prengel C, Utzmann O, Scetbon F, Bernaudin JF, Fajac A: Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Br J Cancer 2005, 93:1175-1181
58. Mills LJ, Poller DN, Yiangou C: Galectin-3 is not useful in thyroid FNA. Cytopathology 2005, 16:132-138
59. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 2005, 12:305-317
60. Aron M, Kapila K, Verma K: Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Indian J Pathol Microbiol 2006, 49:376-380
61. Carpi A, Naccarato AG, Iervasi G, Nicolini A, Bevilacqua G, Viacava P, Collecchi P, Lavra L, Marchetti C, Sciacchitano S, Bartolazzi A: Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer 2006, 95:204-209
62. Kim MJ, Kim HJ, Hong SJ, Shong YK, Gong G: Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol 2006, 50:28-34
63. Torres-Cabala C, Bibbo M, Panizo-Santos A, Barazi H, Krutzsch H, Roberts DD, Merino MJ: Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 2006, 50:518-528
64. Sapio MR, Guerra A, Posca D, Limone PP, Deandrea M, Motta M, Troncone G, Caleo A, Vallefuoco P, Rossi G, Fenzi G, Vitale M: Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer 2007, 14:1089-1097
65. Hooft L, van der Veldt AA, Hoekstra OS, Boers M, Molthoff CF, van Diest PJ: Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules. Clin Endocrinol (Oxf) 2008, 68:252-257
66. Ersoz S, Sert H, Yandi M, Erem C, Mungan S, Ersoz HO, Cobanoglu U, Hacihasanoglu A: The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology. Pathol Oncol Res 2008, 14:457-460
67. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Giovagnoli MR, Monti S, Toscano V, Sciacchitano S, Pennelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bellocco R: Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 2008, 9:543-549
68. Franco C, Martinez V, Allamand JP, Medina F, Glasinovic A, Osorio M, Schachter D: Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol 2009, 17:211-215
69. Fernandez PL, Merino MJ, Gomez M, Campo E, Medina T, Castronovo V, Sanjuan X, Cardesa A, Liu FT, Sobel ME: Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 1997, 181:80-86
70. Cvejic D, Savin S, Golubovic S, Paunovic I, Tatic S, Havelka M: Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression. Histopathology 2000, 37:530-535
71. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, Sueyoshi K, Aikou T, Sato E: Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 2000, 31:428-433
72. Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT, Medeiros-Neto G: Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocr Pathol 2001, 12:275-279
73. Beesley MF, McLaren KM: Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002, 41:236-243
74. Coli A, Bigotti G, Zucchetti F, Negro F, Massi G: Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 2002, 40:80-87
75. Faggiano A, Talbot M, Lacroix L, Bidart JM, Baudin E, Schlumberger M, Caillou B: Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol (Oxf) 2002, 57:813-819
76. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW: Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002, 126:710-713
77. Casey MB, Lohse CM, Lloyd RV: Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol 2003, 14:55-60
78. Feilchenfeldt J, Totsch M, Sheu SY, Robert J, Spiliopoulos A, Frilling A, Schmid KW, Meier CA: Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Mod Pathol 2003, 16:1117-1123
79. Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P, Fontanini G, Ugolini C, Camacci T, De Ieso K, Miccoli P, Pinchera A, Basolo F: Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid 2003, 13:765-770
80. Kovacs RB, Foldes J, Winkler G, Bodo M, Sapi Z: The investigation of galectin-3 in diseases of the thyroid gland. Eur J Endocrinol 2003, 149:449-453
81. Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, Lennard TW: Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2004, 45:493-500
82. Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, Stern Y: Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck 2004, 26:960-966
83. Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR: The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 2004, 122:524-531
84. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS: Usefulness of HBME-1, cytokeratin 19 and galectin- 3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005, 47:391-401
85. Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Yasuoka H, Kakudo K, Inohara H, Kuma K, Miyauchi A: Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. Pathology 2005, 37:296-298
86. Nucera C, Mazzon E, Caillou B, Violi MA, Moleti M, Priolo C, Sturniolo G, Puzzolo D, Cavallari V, Trimarchi F, Vermiglio F: Human galectin- 3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest 2005, 28:106-112
87. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT: Galectin-3, fibronectin-1. CITED-1, HBME1 and cytokeratin- 19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005, 18:48-57
88. Cvejic DS, Savin SB, Petrovic IM, Paunovic IR, Tatic SB, Havelka MJ: Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. Head Neck 2005, 27:1049-1055
89. Cvejic D, Savin S, Petrovic I, Selemetjev S, Paunovic I, Tatic S, Havelka M: Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma. Exp Oncol 2005, 27:210-214
90. Aratake Y, Nomura H, Kotani T, Marutsuka K, Kobayashi K, Kuma K, Miyauchi A, Okayama A, Tamura K: Coexistent anaplastic and differentiated thyroid carcinoma: an immunohistochemical study. Am J Clin Pathol 2006, 125:399-406
91. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA: Diagnostic value of differential expression of CK19. Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 2006, 17:225-234
92. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV: Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol 2006, 17:213-223
93. Rossi ED, Raffaelli M, Mule A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G: Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 2006, 48:795-800
94. Scognamiglio T, Hyjek E, Kao J, Chen YT: Diagnostic usefulness of HBME1, galectin-3. CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 2006, 126:700-708
95. Coli A, Bigotti G, Parente P, Federico F, Castri F, Massi G: Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma. J Exp Clin Cancer Res 2007, 26:221-227
96. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, Jang HC, Park SH, Cho BY, Park SY: Diagnostic value of galectin-3. HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 2007, 22:621-628
97. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F, Schlumberger M: Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid 2007, 17:639-646
98. Torregrossa L, Faviana P, Camacci T, Materazzi G, Berti P, Minuto M, Elisei R, Vitti P, Miccoli P, Basolo F: Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. Hum Pathol 2007, 38:1482-1488
99. Viacava P, Bocci G, Tonacchera M, Fanelli G, DeServi M, Agretti P, Berti E, Goletti O, Aretini P, Resta ML, Bevilacqua G, Naccarato AG: Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules. Thyroid 2007, 17:191-197
100. Weinberger PM, Adam BL, Gourin CG, Moretz WH, 3rd, Bollag RJ, Wang BY, Liu Z, Lee JR, Terris DJ: Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2007, 133:503-510
101. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW: Combined immunostaining with galectin-3, fibronectin-1. CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator- activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 2008, 158:375-384
102. Londero SC, Godballe C, Krogdahl A, Bastholt L, Specht L, Sorensen CH, Pedersen HB, Pedersen U, Christiansen P: Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? Acta Oncol 2007, 1-7
103. Murphy KM, Chen F, Clark DP: Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol 2008, 39:420-426 (Pubitemid 351186691)
104. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M: Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Hum Pathol 2008, 39:1656-1663
105. Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A, Maeda M, Miyoshi E, Kinoshita N, Yoshida H, Furukawa M, Takenaka Y, Takamura Y, Ito Y, Taniguchi N: Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun 2008, 376:605-610
106. Kashima K, Yokoyama S, Daa T, Nakayama I, Nickerson PA, Noguchi S: Cytoplasmic biotin-like activity interferes with immunohistochemical analysis of thyroid lesions: a comparison of antigen retrieval methods. Mod Pathol 1997, 10:515-519 (Pubitemid 27244242)
107. Kim SH, Jung KC, Shin YK, Lee KM, Park YS, Choi YL, Oh KI, Kim MK, Chung DH, Son HG, Park SH: The enhanced reactivity of endogenous biotin-like molecules by antigen retrieval procedures and signal amplification with tyramine. Histochem J 2002, 34:97-103
108. Bussolati G, Gugliotta P, Volante M, Pace M, Papotti M: Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology 1997, 31:400-407 (Pubitemid 27505355)
109. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ: Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008, 36:425-437
110. Raphael SJ: The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia. Endocr Pathol 2002, 13:301-311
111. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM: HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006, 4 Suppl 3:S1-S22; quiz S23-S24
112. Fowler LJ, Lachar WA: Application of immunohistochemistry to cytology. Arch Pathol Lab Med 2008, 132:373-383
113. Carpi A, Nicolini A, Marchetti C, Iervasi G, Antonelli A, Carpi F: Percutaneous large-needle aspiration biopsy histology of palpable thyroid nodules: technical and diagnostic performance. Histopathology 2007, 51:249-257 (Pubitemid 47084004)
114. Pazaitou-Panayiotou K, Capezzone M, Pacini F: Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007, 17:1085-1092 (Pubitemid 350207746)
115. Noguchi S, Yamashita H, Uchino S, Watanabe S: Papillary microcarcinoma. World J Surg 2008, 32:747-753
116. Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S, Krgovic K, Havelka M: Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology 2005, 47:209-214 (Pubitemid 41113125)
117. Berho M, Suster S: Clear nuclear changes in Hashimoto's thyroiditis. A clinicopathologic study of 12 cases, Ann Clin Lab Sci 1995, 25:513-521
118. Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT: Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 2004, 45:39-46 (Pubitemid 38969560)
119. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ: Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 2007, 142:717-727; discussion 727-1719
120. Griffith OL, Melck A, Jones SJ, Wiseman SM: Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 2006, 24:5043-5051 (Pubitemid 46631408)
121. Finley DJ, Zhu B, Barden CB, Fahey TJ 3rd: Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 2004, 240:425-436; discussion 436-1427
122. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 2001, 98:15044-15049
123. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E, Swierniak A: Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 2005, 65:1587-1597
124. Finn SP, Smyth P, Cahill S, Streck C, O'Regan EM, Flavin R, Sherlock J, Howells D, Henfrey R, Cullen M, Toner M, Timon C, O'Leary JJ, Sheils OM: Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Arch 2007, 450:249-260
125. Lubitz CC, Ugras SK, Kazam JJ, Zhu B, Scognamiglio T, Chen YT, Fahey TJ, 3rd: Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 2006, 8:490-498; quiz 528
126. Lubitz CC, Gallagher LA, Finley DJ, Zhu B, Fahey TJ, 3rd: Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 2005, 138:1042-1048; discussion 1048-1049
127. Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET: Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab 2002, 87:4806-4810 (Pubitemid 35247079)
128. Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman KD, Burch HB, Ringel MD: Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2002, 87:4792-4796
129. Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Amino N: Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. Cancer Lett 2003, 199:69-73 (Pubitemid 37088140)
130. Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N: Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma. Cancer Lett 2005, 219:91-96 (Pubitemid 40203175)
131. Pagedar NA, Chen DH, Wasman JK, Savvides P, Schluchter MD, Wilhelm SM, Lavertu P: Molecular classification of thyroid nodules by cytology. Laryngoscope 2008, 118:692-696 (Pubitemid 351496750)
132. Bojunga J, Zeuzem S: Molecular detection of thyroid cancer: an update. Clin Endocrinol (Oxf) 2004, 61:523-530 (Pubitemid 39540353)
133. Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, Andre S, Gabius HJ, Laurent G: Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 2008, 18:705-712
134. Iurisci I, Cumashi A, Sherman AA, Tsvetkov YE, Tinari N, Piccolo E, D'Egidio M, Adamo V, Natoli C, Rabinovich GA, Iacobelli S, Nifantiev NE: Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res 2009, 29:403-410
135. Bartolazzi A, D'Alessandria C, Parisella MG, Signore A, Del Prete F, Lavra L, Braesch-Andersen S, Massari R, Trotta C, Soluri A, Sciacchitano S, Scopinaro F: Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. PLoS One 2008, 3:e3768